Detalhe da pesquisa
1.
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations.
Int J Clin Oncol
; 26(5): 841-850, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33783657
2.
Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.
Asia Pac J Clin Oncol
; 14 Suppl 1: 7-9, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29508940
3.
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
J Clin Oncol
; 24(24): 3831-7, 2006 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16921034